10x Genomics (NASDAQ:TXG – Get Free Report) CEO Serge Saxonov sold 31,000 shares of the stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $62.90, for a total value of $1,949,900.00. Following the transaction, the chief executive officer owned 1,019,249 shares in the company, valued at approximately $64,110,762.10. This trade represents a 2.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Serge Saxonov also recently made the following trade(s):
- On Tuesday, September 22nd, Serge Saxonov sold 25,000 shares of 10x Genomics stock. The shares were sold at an average price of $81.22, for a total transaction of $2,030,500.00.
- On Wednesday, August 26th, Serge Saxonov sold 10,486 shares of 10x Genomics stock. The stock was sold at an average price of $63.69, for a total transaction of $667,853.34.
- On Monday, August 24th, Serge Saxonov sold 18,545 shares of 10x Genomics stock. The stock was sold at an average price of $63.02, for a total transaction of $1,168,705.90.
10x Genomics Price Performance
Shares of NASDAQ TXG traded down $0.91 during trading hours on Friday, hitting $58.19. 2,123,279 shares of the stock were exchanged, compared to its average volume of 3,247,553. The company’s 50 day moving average is $73.92 and its 200 day moving average is $42.57. The firm has a market capitalization of $7.58 billion, a P/E ratio of -111.90 and a beta of 2.03. 10x Genomics has a one year low of $15.12 and a one year high of $102.81.
10x Genomics (NASDAQ:TXG – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.12. The business had revenue of $150.67 million for the quarter, compared to analyst estimates of $147.96 million. 10x Genomics had a negative net margin of 10.84% and a negative return on equity of 8.19%. 10x Genomics’s revenue was up 1.1% compared to the same quarter last year. During the same period last year, the business posted ($0.22) EPS. Research analysts anticipate that 10x Genomics will post -0.74 earnings per share for the current fiscal year.
Hedge Funds Weigh In On 10x Genomics
A number of institutional investors and hedge funds have recently bought and sold shares of TXG. Carolina Wealth Advisors LLC bought a new stake in 10x Genomics in the 3rd quarter valued at $46,000. Fifth Third Bancorp acquired a new stake in 10x Genomics in the 1st quarter worth $50,000. Elevation Wealth Partners LLC grew its position in 10x Genomics by 332.3% in the 2nd quarter. Elevation Wealth Partners LLC now owns 1,487 shares of the company’s stock worth $57,000 after purchasing an additional 1,143 shares during the last quarter. Steward Partners Investment Advisory LLC increased its holdings in shares of 10x Genomics by 240.6% during the 3rd quarter. Steward Partners Investment Advisory LLC now owns 671 shares of the company’s stock worth $61,000 after purchasing an additional 474 shares during the period. Finally, V Square Quantitative Management LLC bought a new position in shares of 10x Genomics during the 3rd quarter worth about $68,000. Institutional investors own 84.68% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on the stock. Piper Sandler upped their price target on shares of 10x Genomics from $47.00 to $80.00 and gave the company a “neutral” rating in a report on Monday, September 28th. Argus initiated coverage on 10x Genomics in a research note on Monday, September 28th. They issued a “buy” rating and a $110.00 price objective on the stock. UBS Group dropped their price objective on 10x Genomics from $90.00 to $61.00 and set a “neutral” rating on the stock in a research note on Friday, November 6th. Canaccord Genuity Group boosted their price objective on 10x Genomics from $60.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Finally, Stephens downgraded 10x Genomics from an “overweight” rating to an “equal weight” rating in a research note on Friday, October 23rd. Five investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, 10x Genomics currently has a consensus rating of “Hold” and an average target price of $68.40.
View Our Latest Research Report on TXG
10x Genomics Company Profile
10x Genomics, Inc. develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue. The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.
Featured Articles
- Five stocks we like better than 10x Genomics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
